TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice

Blood

Volumn 112, Issue 6, 2008, Pages 2474-2483

  Zhou, Yun ^a   Du, Wei ^a   Koretsky, Tara ^b   Bagby, Graver C ^b   Pang, Qishen ^a,c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEOPHOSMIN; TRANSACTIVATOR PROTEIN; HYBRID PROTEIN; NUCLEAR PROTEIN; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FIBROBLAST; GENE ACTIVITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LEUKEMIA CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRELEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REPORTER GENE; SENESCENCE; WILD TYPE; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; INFLAMMATION; LEUKEMIA; PATHOLOGY;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE PRODUCTS, TAT; INFLAMMATION; LEUKEMIA; MICE; NEOPLASTIC STEM CELLS; NF-KAPPA B; NUCLEAR PROTEINS; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS;

EID: 55249113736     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-12-130211     Document Type: Article

References (34)

1. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer. 2006; 6:493-505.
2. Chan WY, Liu QR, Borjigin J, Busch H, Rennert OM, Tease LA, Chan PK. Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth. Biochemistry 1989;28:1033-1039.
3. Feuerstein N, Chan PK, Mond JJ. Identification of numatrin, the nuclear matrix protein associated with induction of mitogenesis, as the nucleolar protein B23: implication for the role of the nucleolus in early transduction of mitogenic signals. J Biol Chem. 1988;263:10608-10612.
4. Nozawa Y, Van Belzen N, Van der Made AC, Dinjens WN, Bosnian FT. Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol. 1996;178:48-52.
5. Subong EN, Shue MJ, Epstein Jl, Briggman JV, Chan PK, Partin AW. Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate. 1999;39:298-304.
6. Tanaka M, Sasaki H, Kino I, SugimuraT, Terada M. Genes preferentially expressed in embryo stomach are predominantly expressed in gastric cancer. Cancer Res. 1992;52:3372-3377.
7. Li J, Sejas DP, Burma, S, Chen, DJ, Pang Q. Nucleophosmin suppresses oncogene-induced apoptosis and senescence and enhances oncogenic cooperation in cells with genomic instability. Carcinogenesis. 2007;28:1163-1170.
8. Selivanova G, lotsova V, Okan I, et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med. 1997;3:632-638.
9. WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res. 1997;57:1442-1446.
10. Fahraeus R, Lain S, Ball KL, Lane DP. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Oncogene. 1998;16:587-596.
11. Schwarze SR, Vocero-Akbani AHo, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999;285: 1569-1572.
12. Asoh S, Ohsawa I, Mori T, et al.. Protection against ischemic brain injury by protein therapeutics. Proc Natl Acad Sci USA 2002;99:17107-17112.
13. L fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci. 2002; 22:5423-5431.
14. Denicourt C. Dowdy SF. Protein transduction technology offers novel therapeutic approach for brain ischemia. Trends Pharmacol Sci. 2003;24: 216-218.
15. L exerts anti-apoptotic activity in vivo. Oncogene. 2003;22:8432-8440.
16. Li J, Sejas DP, Zhang X, et al. TNF-α induces leukemic clonal evolution ex vivo in Fanconi anemia group C stem cells. J Clin Invest. 2007;117:3283-3295.
17. Saccani S, Marazzi I, Beg AA, Natoli G. Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor kappaB response. J Exp Med. 2004;200:107-113.
18. Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature. 2005;437:147-153.
19. Li J, Zhang X, Sejas DP. Pang Q. Negative regulation of p53 by nucleophosmin antagonizes stress-induced apoptosis in human normal and malignant hematopoietic cells. Leuk Res. 2005; 29:1415-1423.
20. Li J, Zhang X, Sejas DP. Bagby GC, Pang Q. Hypoxia-induced nucleophosmin protects cell death through inhibition of p53. J Biol Chem. 2004;279:41275- 41279.
21. Maiguel DA, Jones L, Chakravarty Yang C, Carrier F. Nucleophosmin sets a threshold for p53 response to UV radiation. Mol Cell Biol. 2004;24: 3703-3711.
22. Li J, Sejas DP, Rani R, Koretsky T, Bagby GC, Pang Q. Nucleophosmin regulates cell cycle progression and stress response in hematopoietic stem/progenitor cells. J Biol Chem. 2006;281: 16536-16545.
23. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749-759.
24. Dhar SK, Lynn BC, Daosukho C. Clair DK. Identification of nucleophosmin as an NF-κB coactivator for the induction of the human SOD2 gene. J Biol Chem. 2004;279:28209-28219.
25. Hingorani K, Szebeni A, Olson MO. Mapping the functional domains of nucleolar protein B23. J Biol Chem. 2000;275:24451-24457.
26. Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Gell Biol. 2004:24:985-996.
27. Korgaonkar C, Hagen J, Tompkins V, et al. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol. 2005;25:1258-1271.
28. Lenz HJ. Glinical update: proteasome inhibitors in solid tumors. Gancer Treat Rev. 2003;1(suppl): 41-48.
29. Greten FR, Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 2004;206:193-199.
30. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature. 2004;431:405-406.
31. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition MDM2. Cell. 1997;91:325-334.
32. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307-310.
33. Webster GA, Perkins ND. Transcriptional cross talk between NF-Kappa;B and p53. Mol Cell Biol. 1999; 19:3485-3495.
34. Gurova KV, Hill JE, Guo C, etc. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A. 2005;102:17448-17453.